Pulmonx Reports Mixed Q4 Results, Flat 2026 Guidance, Secures $60M Debt Facility
LUNG sits 17% above its 52-week low of $1.31.
Summary
Pulmonx reported Q4 2025 financial results, issued flat 2026 revenue guidance, and announced a significant $60 million debt refinancing and cost restructuring initiative.
Key Events · Earnings and Guidance · LUNG
-
Mixed Q4 and Full Year 2025 Financial Results
Worldwide revenue for Q4 2025 decreased 5% year-over-year to $22.6 million, while full year 2025 worldwide revenue increased 8% to $90.5 million. The company reported a net loss of $10.4 million for Q4 2025 and $54.0 million for the full year 2025.
-
Flat Full Year 2026 Revenue Guidance
Pulmonx expects full year 2026 revenue to be in the range of $90 million to $92 million, indicating minimal growth from 2025. Gross margin is projected at approximately 75%.
-
Significant Debt Refinancing Secured
The company refinanced its existing debt, securing up to $60 million in committed capital under a new 5-year interest-only credit facility that extends debt maturity to 2031. This provides substantial liquidity relative to the company's market cap.
-
Cost Restructuring Initiative Underway
Pulmonx executed a cost restructuring initiative aimed at reducing operating expenses while maintaining key commercial and clinical investments, with total operating expenses for 2026 expected between $113 million and $115 million.
Analysis · LUNG · Industrial Applications And Services
Pulmonx Corporation reported a mixed financial performance with a decline in Q4 2025 revenue and flat revenue guidance for 2026, indicating ongoing growth challenges. However, the company significantly strengthened its balance sheet by securing a new $60 million credit facility, extending debt maturity to 2031, and implementing cost restructuring. For a company with a market capitalization of approximately $59 million, this debt refinancing is a critical liquidity event that provides substantial financial runway and de-risks near-term operations, despite the continued net losses. Investors should monitor the company's ability to reaccelerate commercial growth and achieve profitability with this extended financial flexibility.
At the time of this filing, LUNG was trading at $1.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $59.4M. The 52-week trading range was $1.31 to $8.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.